



Care For You

**Pursuing the satisfaction and happiness of its customers, shareholders, and employees, ChoongWae aims to make contribution to building up a bright healthy society by providing innovative technologies, products and services which support healthy life of human beings.**


- 1945 Establishment of Chosun ChoongWae Pharmaceuticals with injection products
- 1976 Initial public Offering  
List on the Korea Stock Exchange Market
- 1982 Corporation name change  
ChoongWae Pharma Corporation



- 1983 Establishment of ChoongWae Research Labs.
- 1992 Establishment of C & C Research Labs.



- 2001 Establishment of Seattle Research Labs.
- 2001 FDA approval for Q-roxin as a new drug



## Choongwae Pharma Corporation (since 1945)

Pharmaceuticals (ETC & OTC)

Bulk Pharmaceuticals

Diagnostics

Homecare Products

Medical Instruments

Choong Wae Medical  
Medical Equipment (since 1972)

Choong Wae Industrial  
Industrial Chemicals (since 1988)

Daeyoo Pharma  
Dermatology (since 1990)


C&C Research Labs.  
Discovery & Optimization (since 1992)

Choong Wae IT  
Total Medical Info. System (Since 1999)

Seattle Research Labs.  
Research lab. (since 2001)

Choong Wae Corp.  
I.V. Solution Business (since 2003)


# Choongwae Group Sales Turnover (2004)



**Total Group Sales Turnover**


**413 Billion Won**

# Pharma Sales by Therapeutic Class




2004 Pharmaceutical Sales in Korea

# Sales Trend of CWP



Unit : Bil. won



G/R : Growth Rate

# Leading Pharmaceutical Companies




Unit : MIL.won

	Company	2004	2003	G/R
1	DongA	541,208	492,485	9.9
2	Yuhan	340,404	306,595	11.0
3	HanMI	317,011	243,457	30.2
4	ChoongWae	303,167	282,359	7.4
5	Pfizer	257,745	244,534	5.4
6	HanDok	241,497	222,777	8.4
7	G S K	228,889	222,253	2.9
8	Jell	221,087	188,614	17.2
9	LG	213,836	179,037	19.3
10	Bayer	208,240	170,050	22.5
10 company's Total		2,872,684	2,552,161	13.4

(Basis of The Health & Social Daily News, 2005)



AREA	COMPANY	1st YEAR AGREED	LICENSED PRODUCTS
JAPAN	CHUGAI	1971	Ulcerlmin, Neutrogin, Sigmart, Alfarol etc.
	KYOWA HAKKO	1979	MMC-C, Leunase
	S.K.K. (SANWA)	1982	Adelavin 9, Argamate
	KISSEI	1982	Rizaben, Domenan, Xanbon
	MITSUBISHI	1989	Surfacten
	SENJU	1996	Bestron, Lomeflon, Pranopulin etc.
	Abbott Japan(Hokuriku)	1997	Ganaton
	MEIJI	2000	Habekacin
	SATO	2001	Surazin A, Acnepel
	KOWA	2003	Livalo
EUROPE	VIFOR INT.	1975	Ferrum, Venoferrum
	SOLVAY	1977	Dumirox, Duphalac, Femoston, Duphaston etc
	B.BRAUN	1988	Nutriflex
	HELSINN S.A.	1989	Mesulid
	HOFFMAN LA ROCHE	1994	Recormon
U.S.A.	MENARINI	2002	Bifril
	ABBOTT	1984	Gerolan, Forane
	CEPHALON	2000	Provigil, Gabtril
	3M	2000	Tambocor




# R&D Pipeline for New Drug



Area/Product	Indication	Origin	Research	Preclinical	PI	PII	PIII	R
<b>Cardiology</b>								
Zofenopril (Bifril)	Hypertension	License-in						
Pitavastatin (Livalo)	Hyperlipidemia	License-in						
KCB328	Arrythmia	In-house						
<b>Nephrology</b>								
<u>Lathanum (Fosrenol)</u>	<u>Hyperphosphataemia</u>	<u>License-in</u>						
<b>CNS</b>								
Tiagabine(Gabitril)	Epilepsy	License-in						
CW241532	Stroke	In-house						
<b>Inflammation</b>								
Balofloxacin (Q-roxin)	UTI, OB&Gyn	In-house						
<b>Oncology</b>								
TCF-4	Colon cancer	In-house						
<b>Metabolism</b>								
Mitiglinide (Glufast)	Diabetes	License-in						
<b>Urology</b>								
Silodocin (Trufast)	BPH	License-in						

## SHIWHA Plant

- u Total land 9,900 m<sup>2</sup>
- u Building Area (Covered facility) 8,500 m<sup>2</sup>
- u In compliance with **GMP guideline**



As of June 8, 2004

# Master Plan of New Factory

**Land Space ; 143,697 m<sup>2</sup>**

**Building Space ; 98,453 m<sup>2</sup>**

**1<sup>st</sup> Production Line Running ; September, 2006**



## toward Global Healthcare Company

Operation of Dang-jin Factory	2006	<ul style="list-style-type: none"> <li>• Leap up in IV sales</li> <li>• Export of IV produced under EU GMP</li> <li>• Export of Plant Engineering</li> </ul>
Launch of New ETC Products in Time	2005	• Livalo
	2006	<ul style="list-style-type: none"> <li>• Glufast</li> <li>• Fosrenol</li> <li>• Gabitril</li> </ul>
	2008	• Silodosin
Successful Overseas Biz of API	2005 ~	<ul style="list-style-type: none"> <li>• Itraconazole</li> <li>• Imipenem</li> </ul>
R&D Tech License Out	2005	• CBP Program
	2007	• NFKB Program
Successful Entrance into New Biz	2005	<ul style="list-style-type: none"> <li>• Neutraceutical food</li> <li>• Diabetes shops etc.</li> </ul>

◆ 1 Trillion of Turnover, 100 Billion of Ordin

**Global Health  
Company**

